Clinical Trial

Experimenta Treatment for Advanced or Metastatic Cancers

Study Description

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum- tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - ZW49

Dose Escalation: ZW49 administration IV Q2W or Q3W at dose levels determined by the SMC Expansion: MTD(s) or RD(s) identified in the dose-escalation part of the study

Additional Information

Official Study Title

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Clinical Trial ID

NCT03821233

ParticipAid ID

dNkWKe